Aurobindo Pharma on track to develop complex products, expand global footprint
The facility will start filing new injectable products in FY23 with earliest possible commercialisation in FY24, the drugmaker added.;

Advertisement
Hyderabad: Aurobindo Pharma remains focussed on developing complex and differentiated products in multiple areas comprising oncology, hormonal products, biosimilars, depot injections and vaccines to drive the next phase of growth, as per its Annual Report for 2021-22. The Hyderabad-based firm also said it is in the process of commissioning the capacities for some of the complex therapeutic areas, adding that it is committed to grow in its key geographies of the US, Europe and other growth markets.
"In the US, around 220 abbreviated new drug applications (ANDAs) are awaiting final approval..With the pandemic situation easing, your company will resume its development trajectory, with a focus on developing a product range of complicated injectables," it informed shareholders.
In Europe, the company has filed applications for 58 products and is awaiting approval, the drug major said.
Additionally, there are nearly 200 products under development in general oral/ general/ oncology product categories, which will be launched in the next two to three years.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.